News

Collaboration with American College of Cardiology could result in new health-outcomes results

Nearly 100 cargo stations have been enhanced for pharma cold-chain distribution

First of what are expected to be many global 3PL sites, especially for specialty pharmaceuticals

$2-billion acquisition brings a $5-billion/yr PBM to Rite Aid's 4,600 retail stores

Service eases the management of domestic US shipments to trading partners and patients

Vaccine trials will continue without a clear path forward

KoolTemp GTS Instant avoids use--and cost--of refrigerants

Whole blood use is declining while plasma-derived product consumption rises

Annual specialty-distribution study focuses trend in oncology, chronic diseases

Company uses online media to promote fill rates by over 50%

$296-million bid makes it the 'stalking horse' buyer in Dendreon auction

Roughly 40% are for rare diseases; PD-1 oncolytics capture industry attention

Mapi Group casts itself as a leading 'health research and commercialization' player

'Stay tuned' for interactions directly with pharma companies, says CEO Jeff Tangney

So long WAG, hello to WBA as pharma manufacturers look at a consolidating buyer landscape

Pharmacists' ranking, continuing a two-year decline, is now neck-and-neck with doctors

Express Scripts touts a 'fundamental change' in drug pricing; others would call it negotiating a discount

Acquisition builds on Dohmen's rare-disease business

Poltraf acquisition adds to a network of 14 facilities serving Eastern and Western Europe

Will formularies become a consumer's concern for healthcare provision?

The broad changes taking place in the pharma supply chain this year are a relevant focus for the annual conference and exhibition

FDA enforcement delay to May 1 isn't slowing down project work

Company hires Kevin O'Donnell, cold chain expert, to build out its Biologistex shipping service

Cloud computing opens a new array of benefits--and challenges--to data-sharing

Identity Management

Persistent drug shortages are mostly attributable to manufacturing quality problems, but the economics of low-margin generic manufacturing challenge the industry

When state and federal governments are involved, prices and reimbursements have both regulatory and financial consequences